drugset

drugset / Trial / NCT02290041

Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response

NCT02290041 ↗

Phase 1/2 Completed 5 enrolled Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud Iniciativa Andaluza en Terapias Avanzadas · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

Phase I/IIClinical trial, proof of concept, double blind, and placebo-controlled, randomized 2:1 (MSCs: placebo), total sample size is 15 subjects

Timeline

Start: 2017-02-08
Primary completion: 2019-07-30
Completion: 2019-07-30

Publications

Trujillo-Rodriguez M, Viciana P, Rivas-Jeremias I, Alvarez-Rios AI, Ruiz-Garcia A, Espinosa-Ibanez O, Arias-Santiago S, Martinez-Atienza J, Mata R, Fernandez-Lopez O, Ruiz-Mateos E, Gutierrez-Valencia A, Lopez-Cortes LF. Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial. Stem Cells Transl Med. 2021 Apr;10(4):534-541. doi: 10.1002/sctm.20-0213. Epub 2020 Dec 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Autologous Adipose-Derived Mesenchymal Stromal Cells	Cell therapy	1e+06 cells/kg	Intravenous

Indications

No indication recorded.